Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Metso Corporation: Managers' transactions – Ian Pearce

Metso Corporation’s stock exchange release on April 29, 2024, at 3:00 p.m. EESTMetso Corporation has received the following disclosure under EU Market Abuse Regulation No 596/2014, regarding managers' or their closely associated persons' transactions with Metso's shares. Person subject to the notification requirementName: Pearce, IanPosition: Member of the Board Initial NotificationReference number: 549300R0VN9C371W0E07_20240429090438_246 IssuerName: Metso CorporationLEI:

Metso Corporation: Managers' transactions – Niko Pakalén

Metso Corporation’s stock exchange release on April 29, 2024, at 3:00 p.m. EESTMetso Corporation has received the following disclosure under EU Market Abuse Regulation No 596/2014, regarding managers' or their closely associated persons' transactions with Metso's shares. Person subject to the notification requirementName: Pakalén, NikoPosition: Member of the Board Initial NotificationReference number: 549300R0VN9C371W0E07_20240429090438_253 IssuerName: Metso CorporationLEI:

Metso Corporation: Managers' transactions – Terhi Koipijärvi

Metso Corporation’s stock exchange release on April 29, 2024, at 3:00 p.m.Metso Corporation has received the following disclosure under EU Market Abuse Regulation No 596/2014, regarding managers' or their closely associated persons' transactions with Metso's shares. Person subject to the notification requirementName: Koipijärvi, TerhiPosition: Member of the Board Initial NotificationReference number: 549300R0VN9C371W0E07_20240429090438_251 IssuerName: Metso CorporationLEI:

NYAB Plc: Resolutions of the Extraordinary General Meeting

NYAB PlcCOMPANY ANNOUNCEMENT29 April 2024 at 15:00NYAB Plc: Resolutions of the Extraordinary General Meeting NYAB Plc’s (“NYAB” or the “Company”) Extraordinary General Meeting was held today, on 29 April 2024, in Helsinki. The Extraordinary General Meeting resolved on the cross-border conversion of the Company and made other resolutions relating to the cross-border conversion, resolved to issue new shares to the Company itself, and resolved to authorize the Board of Directors to resolve on issuances as follows: Resolutions relating to the cross-border conversion of NYAB Plc The

Spinomenal Unleashes Book of Rampage - A Moonlight Tale

Leading iGaming content provider Spinomenal has expanded its wildly popular Book of Rampage slots collection with the release of Book of Rampage - A Moonlight Tale. This game begins the next chapter of the Wildlife series.This title whisks players into an adventure-filled wilderness, brought to life with an absorbing soundtrack under the stars. Book of Rampage - A Moonlight Tale features a snorting buffalo, a majestic horse, a vicious snake, and a ferocious wolf as its medium symbols.At the heart of this enthralling game is the Golden buffalo book, serving as both the Wild and Scatter

Swedavia’s interim report for Q1 of 2024: More passengers, stronger commercial offering, improved range of routes and destinations led to increased net revenue, improved EBITDA and stronger cash flow

Net revenue for the period increased by SEK 154 M to SEK 1,443 M. Higher passenger volume and fee adjustments have contributed to this increase. Cash flow for the period was positive and amounted to SEK 57 M, an increase of SEK 76 M compared with the previous year. Swedavia reported EBITDA of SEK 175 M for the quarter, which is an increase of SEK 55 M compared with the previous year. Operating income was SEK -217 M, which is on a par with last year’s operating income. Preparations were made during the period for the increased dimensioning of operations, which affected operating income.

Q1 report 2024: CEO presentation and Q&A

Analyst Mathias Carlson interviews CEO Torbjörn Saxmo after the publication of the Q1 report. Torbjörn briefly presents the company and the key points from the quarter. They discuss margin development, IMU deliveries to Saab, intensified sales efforts, and the financing of continued growth.Watch the presentation and Q&A here   About Kebni AB (publ)Kebni has a long history and extensive experience in advanced inertial sensing solutions as well as satellite antenna solutions. The company, headquartered in Stockholm, is a leading supplier

NCC to build 219 rental apartments in Skellefteå, Sweden

NCC has signed an agreement with Skebo to construct 219 rental apartments at Anderstorpsgården in Skellefteå. The project is a turnkey contract with an order value of approximately SEK 320 million. Map over Anderstorpsgården, Skellefteå NCC’s assignment includes the new production of rental apartments in varying sizes distributed between tower blocks, low-rise buildings and row houses. Project planning will commence in spring 2024 and construction will start in autumn 2024. The neighborhood will be ready for occupancy in late 2026 or early 2027. “Demand remains strong for

Vestas – Q1 2024 conference call

Vestas Wind Systems A/S, Aarhus,Investor News, 29 April 2024 Vestas expects to disclose our Interim Financial Report, First Quarter 2024 on 2 May 2024. On the day of the release, Vestas will host a conference call, in which our CEO and CFO will present the results via an audiocast, which can be followed live or replayed. The meeting will be held in English. Time2 May 2024 at 10.00 am CEST (09.00 am BST)   AudiocastTo livestream or replay the presentation, go to Audiocast link . Q&AAt the end of

Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director

LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.    As Clinical Laboratory Director, Dr. Ford will lead lab operations as well as research and development of Immunovia’s next-generation test. Her primary responsibilities will be staffing, developing, and overseeing the laboratory team; quality assurance and regulatory compliance; and facilitating collaboration and communication with external partners,

Two acquisitions in Finland contribute positively

The first quarter: January – March ·Net sales amounted to 326 MSEK (326) ·Order intake increased by 44 percent to 352 MSEK (245) ·Order backlog increased by 12 percent to 1,392 MSEK (1,241) ·Adjusted operating profit (EBITA) amounted to 16 MSEK (28) ·Operating profit (EBITA) amounted to 13 MSEK (23) ·Net profit after tax amounted to 2 MSEK (14) ·Earnings per share amounted to 0.10 SEK (0.63) ·Operating cash flow amounted to 18 MSEK (-11) Events during the quarter and since the end of the quarter ·January 22 Balco Group

Sectra and Leica Biosystems first in the world to gain FDA clearance to utilize DICOM images for pathology diagnostics

Linköping, Sweden – April 29, 2024 – International medical imaging IT and Cybersecurity company Sectra’s  (STO: SECT B) digital pathology solution together with Leica Biosystems, Imaging, Inc.’s Aperio GT 450 DX have received a 510(k) clearance by the US Food & Drug Administration (FDA). This is the first time an FDA clearance within digital pathology allows the use of DICOM images for pathology diagnostics, which marks a significant step towards standardization in this field.Sectra received its first FDA clearance during the pandemic, in 2020. The pandemic made the

Peab develops New Bodø Airport

Peab has been commissioned to develop New Bodø Airport as the project moves from development to implementation. The customer is Avinor and the contract is worth NOK 3.3 billion.The project comprises the construction of a new runway, taxiways and parking spaces for aircraft. Preparatory work has already been carried out in the area such as removal of vegetation, demolition of old infrastructure and blasting. "This is a historic contract and the largest Peab has received in Norway. I would like to thank Avinor for entrusting us and our close cooperation in the first phase of the project.

Securitas AB to publish the Interim Report January-March 2024 on May 8, 2024

Securitas AB will publish the Interim Report January-March 2024 on Wednesday May 8, 2024, at 8.00 a.m. (CEST).8.00 a.m. (CEST) Report releaseThe report will be sent as a press release from Cision (www.cision.se) and will automatically be published on www.securitas.com when released.  9.00 a.m. (CEST) Presentation slides availableFor presentation slides, follow the linkwww.securitas.com/en/investors/financial-reports-and-presentations  9.30 a.m. (CEST) Telephone conference and audio castAnalysts and media are invited to participate in a telephone conference at 9.30 a.m.

Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina

LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces that the company will move its lab and U.S. headquarters to Research Triangle Park in North Carolina in May 2024.   The move to Research Triangle Park follows Immunovia’s successful model development study, announced on April 22, 2024 , and the successful

Result of Extraordinary General Meeting

Monday, 29 April 2024 KR1 plc (“KR1” or the “Company”) Result of Extraordinary General Meeting KR1 plc (KR1:ASE), a leading digital asset investment company, is pleased to announce that the resolution authorising KR1 to make market purchases of up to 14.99 per cent. of the Company’s issued ordinary share capital (as set out in the announcement of the Company dated 11 April 2024) was duly passed on a poll at the Extraordinary General Meeting of the Company held today. The results of the poll were as follows: +------------+----------+-----+-------+-------+----------+---------

Scandi Standard –First quarter presentation

Scandi Standard will publish its report for the first quarter of 2024 on Friday, 3 May 2024, at 07.30 CET.     Conference call at 08.30 CET The company will host a conference call for the financial community at 08.30 CET on the same day. The conference call will be hosted by Jonas Tunestål, CEO, and Fredrik Sylwan, CFO.    Dial-in numbers:United Kingdom (toll free): +44 800 358 1035  United Kingdom: +44 20 3936 2999 Sweden: +46 10 884 80 16USA (toll free): +1 855 979 6654USA: +1 646 787 9445All other places 

Eklund Foundation for Odontological Research and Education opens for applications of up to €250,000

Researchers within dentistry will soon be able to apply for grants of up to €250,000, which is the total sum allocated by the Eklund Foundation in 2024. The application portal will be open 1-31 May, welcoming applicants from all parts of the world in all fields of dentistry.Both experimental and clinical studies within all fields of dentistry are accepted, but the foundation will prioritise projects that can be related to periodontology, implantology, or cariology. Researchers may apply for funding for a project in its entirety or for part of a project.   Even though the application

poLight ASA: Approval and Publication of Supplemental Prospectus

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Reference is made to the stock exchange announcement by poLight ASA (the "Company" or "poLight") on 24 April 2024 regarding the publication of its audited consolidated financial statements as at, and for the year ended, 31 December 2023 (the "2023 Financial Statements"), and to the stock

BioStock: BioInvent selected to present at ASCO in Chicago

BioInvent has been selected to present two posters at the American Society for Clinical Oncology Annual Congress (ASCO 2024) in Chicago from May 31 to June 4. The presentations will focus on data from the company’s clinical studies with the lead drug candidates BI-1808 and BI-1206, both in phase I/IIa development in combination with MSD’s Keytruda. BI-1808 is also evaluated as single agent, which will also be included in the presentation.Read the article at biostock.se: https://www.biostock.se/en/2024/04/bioinvent-selected-to-present-at-asco-in-chicago/ This is a press release from

No updates on the Optomed Aurora AEYE FDA clearance process

Optomed Plc Stock Exchange Release 29 April 2024 at 13:20, Helsinki No updates on the Optomed Aurora AEYE FDA clearance process Optomed is together with its partner AEYE Health in the process of obtaining a clearance for the AI fundus camera Optomed Aurora AEYE.   At this stage, Optomed does not have any new information regarding the FDA clearance process. Optomed will update market as new information becomes available.   Optomed Plc Further enquiries Juho Himberg, CEO, juho.himberg@optomed.com       Optomed in Brief  Optomed is a Finnish medical

Teesside University students creating AI controlled self-driving car

Students from Teesside University are helping to develop an artificial intelligence (AI) controlled self-driving car, with testing sessions already taking place on campus.Led by Dr Alexander Ellin in the University’s School of Computing, Engineering & Digital Technologies, the team of students and staff are creating the AI controlled car as a test vehicle to help students compete in the renowned IMECHE engineering competition Formula Student. The Formula Student competition, held each year at legendary motor racing circuit Silverstone, is Europe's best known educational engineering

Section 430(2b) statement

29 April 2024   Moonpig Group plc Section 430(2B) Companies Act 2006 Statement Moonpig Group plc (the “Company”) announced on 26 April 2024 that Simon Davidson had resigned as a director of the Company with effect from 25 April 2024.  Under the Relationship Agreement between the Company and Exponent Private Equity LLP (“Exponent”) Simon’s fees as Exponent’s Nominee Director are paid directly to Exponent and will be paid up to and including the date of termination of 25 April 2024. No other remuneration payment will be made by the Company to Simon or to Exponent after Simon

Vattenfall's Annual General Meeting 2024

Vattenfall's Annual General Meeting 2024Vattenfall’s owner was represented at the AGM voting by Gustaf Hygrell at the Ministry of Finance. Annual General Meeting decisions: Adoption of balance sheet and income statement The AGM adopted the income and balance sheet for Vattenfall AB and the Vattenfall Group. Dividend The AGM decided on a dividend distribution of SEK 4 000 000 000 to the owner of the parent company for 2023. Discharge of liability The AGM decided to discharge the members of the board and the CEO from liability. Renumeration report and guidelines for

There are no items matching the current filter
There are no more items matching the current filter
Back to top